Wednesday, September 16, 2009

Vol. 15, No. 18

TRIGGER
The Twice-Monthly Electronic Newsletter on the Biology of Tissue Factor, Factor VII and TFPI
Vol. 15, No. 18 September 15, 2009
(The next issue will be on October 1, 2009)
__________________________________________________________
TRIGGER is also available by RSS Feed:
http://feeds.feedburner.com/blogspot/glro
and BLOG:
http://trigger-tf7.blogspot.com/
__________________________________________________________
ANNOUNCEMENTS
TRIGGER IS NOW AVAILABLE BY RSS FEED AND BLOG:
Beginning today, we are making each TRIGGER issue available on the Internet as an RSS feed and also posting the issue on a blog, both of which are maintained by Pierre Neuenschwander. This is in addition to the regularly e-mailed version you have all been receiving. Please note that anyone submitting an item for Trigger will be given the option of including it only in the e-mailed version. It is therefore possible that some items in the e-mailed version of Trigger might be missing from the RSS or blog versions. But this will probably be uncommon.
Here are the links.

TRIGGER RSS feed:
http://feeds.feedburner.com/blogspot/glro

TRIGGER blog entries:
http://trigger-tf7.blogspot.com/

-Pierre Neuenschwander and Jim Morrissey
__________________________________________________________
PAPERS IN PRESS
AUTHORS: Thomas H. Yun and James H. Morrissey
TITLE: Polyphosphate and omptins: novel bacterial procoagulant agent
JOURNAL: the Journal of Cellular and Molecular Medicine
ABSTRACT: Derangement of the blood clotting system contributes strongly to multiple organ failure in severe sepsis. In this review, we examine two microbial modulators of the clotting system: polyphosphates and omptins. Polyphosphates are linear polymers of inorganic phosphate that are abundant in the acidocalcisomes of prokaryotes and unicellular organisms as well as in the dense granules of human platelets. Polyphosphates modulate hemostasis by: 1) triggering clotting via the contact pathway; 2) accelerating the activation of coagulation factor V (a key cofactor in blood clotting); and 3) causing fibrin to form clots whose fibrils are thicker and more resistant to fibrinolysis. While polyphosphates are found in all prokaryotes, omptins have a more limited distribution among certain Gram-negative species. Omptins are outer membrane aspartyl proteases which were recently found to proteolytically inactivate tissue factor pathway inhibitor (TFPI), the main inhibitor of the initiation phase of blood clotting. Omptin activity against TFPI requires lipopolysaccharide without O-antigen (rough LPS) such as is found on the surface of Yersinia pestis, the etiologic agent of plague. Interestingly, expression of Pla, the Yersinia pestis omptin, has a demonstrated virulence role in converting plasminogen into the fibrinolytic enzyme plasmin, which would seemingly antagonize any procoagulant effect of TFPI inactivation. However, since the rate of TFPI inactivation is much higher than the rate of plasminogen activation, we hypothesize that Pla may have a dual function in supporting the bubonic form of plague which is unique to Yersinia pestis.
SUBMITTED BY: Jim Morrissey
__________________________________________________________
POSTDOCTORAL POSITION AVAILABLE

A Post-Doctoral Position is available in the Department of Pathology and Laboratory Medicine and the program in Hemostasis and Thrombosis at the University of North Carolina at Chapel Hill to study mechanisms contributing to hemostasis and thrombosis. Our group uses in vitro, ex vivo, and in vivo approaches to examine the effects of clotting factors, cellular activity, and flow on clot formation, structure and stability. The current position is to elucidate biochemical and physical mechanisms that promote fibrin stability. Highly motivated individuals with good communication skills and previous experience in coagulation research and/or fluid mechanics are encouraged to apply.
Applicants should possess a PhD or MD/PhD degree. Preference will be given to those individuals who provide a summary of how their interests might fit into the current focus areas of the lab.
Competitive salary and benefits are offered.

Please send CV, half-page description of research interests, and contact information for three references to: Dr. Alisa Wolberg. (alisa_wolberg AT med DOT unc DOT edu). Please use the subject line: Postdoc applicant.
UNC-CH is an equal opportunity employer.
_________________________________________
RECENT PUBLICATIONS ON TISSUE FACTOR, FACTOR VII, AND TFPI
Papers are culled from NLM MedLine (PubMed). Titles in square brackets indicate that the paper was not published in English. References that lack volume or page numbers are typically electronic pre-publications (E-pubs) ahead of the print publication; if so, the final citation with volume and page numbers may or may not appear in a future issue of Trigger.
THE FOLLOWING LINK WILL TAKE YOU TO THE ENTIRE LIST OF THIS ISSUE'S PUBLICATIONS IN A PUBMED "COLLECTION":
http://www.ncbi.nlm.nih.gov/sites/myncbi/collections/public/1dEUkTcNF0jLFxmiybSXM7q/

Blann A, Shantsila E, and Shantsila A (2009) Microparticles and arterial disease. Semin Thromb Hemost 35:488-496.
http://www.ncbi.nlm.nih.gov/pubmed/19739039

Borawski J, Gozdzikiewicz J, Dubowski M, Pawlak K, and Mysliwiec M (2009) Tissue factor pathway inhibitor release and depletion by sulodexide in humans. Adv Med Sci 54:32-36.
http://www.ncbi.nlm.nih.gov/pubmed/19731406

Cassinello Ogea C, Cotera Usua I, Cortes Franco S, and Felix Lucia J (2009) [Intraoperative use of activated recombinant factor VII in a patient with brain cancer]. Rev Esp Anestesiol Reanim 56:394-396.
http://www.ncbi.nlm.nih.gov/pubmed/19725350

Cheng CY, Sun Y, Wen ZB, He XF, Wang GF, Lin GQ, Jiang HH, Tian XM, and He SL (2009) [Effects of tetramethylpyrazine on thrombin-induced tissue factor expression in vascular endothelial cells.]. Nan Fang Yi Ke Da Xue Xue Bao 29:1743-1747.
http://www.ncbi.nlm.nih.gov/pubmed/19726327

Dutton RP, Hauser C, Boffard K, Dimsitts J, Bernard G, Holcomb J, Leppaniemi A, Tortella B, and Bouillon B (2009) Scientific and logistical challenges in designing the CONTROL trial: Recombinant factor VIIa in severe trauma patients with refractory bleeding. Clin Trials
http://www.ncbi.nlm.nih.gov/pubmed/19737846

Eisses MJ, Richards M, Joffe D, Geiduschek JM, and Chandler WL (2009) The response of hemostatic marker levels to activated factor VII in a neonate following cardiopulmonary bypass. Case Report Med 2009:420152
http://www.ncbi.nlm.nih.gov/pubmed/19730751

Ellis DJ, Usman MH, Milner PG, Canafax DM, and Ezekowitz MD (2009) The first evaluation of a novel vitamin K antagonist, Tecarfarin (ATI-5923), in patients with atrial fibrillation. Circulation
http://www.ncbi.nlm.nih.gov/pubmed/19738136

Erez O, Gotsch F, Mazaki-Tovi S, Vaisbuch E, Kusanovic JP, et al. (2009) Evidence of maternal platelet activation, excessive thrombin generation, and high amniotic fluid tissue factor immunoreactivity and functional activity in patients with fetal death. J Matern Fetal Neonatal Med 22:672-687.
http://www.ncbi.nlm.nih.gov/pubmed/19736615

Faust K, Troger B, Kahl F, Schumacher M, Gopel W, and Hartel C (2009) Successful use of recombinant factor VIIa in a preterm infant with life-threatening haematuria. Blood Coagul Fibrinolysis
http://www.ncbi.nlm.nih.gov/pubmed/19730247

Horstman LL, Jy W, Bidot CJ, Nordberg ML, Minagar A, Alexander JS, Kelley RE, and Ahn YS (2009) Potential roles of cell-derived microparticles in ischemic brain disease. Neurol Res 31:799-806.
http://www.ncbi.nlm.nih.gov/pubmed/19723448

Ingelmo Ingelmo I, Rama-Maceiras P, Fàbregas Julià N N, and Hernandez PJ (2009) [Use of activated recombinant factor VII in patients with brain injury or undergoing brain surgery]. Rev Esp Anestesiol Reanim 56:339-342.
http://www.ncbi.nlm.nih.gov/pubmed/19725340

Kasthuri RS, Taubman MB, and Mackman N (2009) Role of tissue factor in cancer. J Clin Oncol
http://www.ncbi.nlm.nih.gov/pubmed/19738116

Khorana AA and Connolly GC (2009) Assessing risk of venous thromboembolism in the cancer patient. J Clin Oncol
http://www.ncbi.nlm.nih.gov/pubmed/19720906

Kim JS, Park DW, Lee HK, Kim JR, and Baek SH (2009) Early growth response-1 is involved in foam cell formation and is upregulated by the TLR9-MyD88-ERK1/2 pathway. Biochem Biophys Res Commun
http://www.ncbi.nlm.nih.gov/pubmed/19737531

Liang W, Cheng J, Liu R, Wang JP, Mu JG, Wang QH, Wang HJ, and Ma D (2009) Peptide corresponding to the C terminus of tissue factor pathway inhibitor inhibits mesangial cell proliferation and activation in vivo. Peptides
http://www.ncbi.nlm.nih.gov/pubmed/19720104

Livnat T, Zivelin A, Tamarin I, Guetta V, and Salomon O (2009) Thrombin generation assay as a possible tool for assessment of reduced activity of clotting factors induced by antiphospholipid antibodies and in-vitro evaluation of treatment options. Blood Coagul Fibrinolysis
http://www.ncbi.nlm.nih.gov/pubmed/19730246

Lockwood CJ, Paidas M, Murk WK, Kayisli UA, Gopinath A, Huang SJ, Krikun G, and Schatz F (2009) Involvement of human decidual cell-expressed tissue factor in uterine hemostasis and abruption. Thromb Res
http://www.ncbi.nlm.nih.gov/pubmed/19720393

Lopez BR, Aeschlimann DN, Carvajal FC, and Lema FG (2009) [Recombinant activated factor VII for perioperative bleeding.]. Rev Med Chil 137:837-843.
http://www.ncbi.nlm.nih.gov/pubmed/19746288

Marzano AV, Tedeschi A, Spinelli D, Fanoni D, Crosti C, and Cugno M (2009) Coagulation activation in autoimmune bullous diseases. Clin Exp Immunol 158:31-36.
http://www.ncbi.nlm.nih.gov/pubmed/19737228

McMullan DM (2009) Relative risks of recombinant factor VII. Pediatr Crit Care Med 10:604-605.
http://www.ncbi.nlm.nih.gov/pubmed/19741450

Pawlak K, Mysliwiec M, and Pawlak D (2009) Haemostatic system, biochemical profiles, kynurenines and the prevalence of cardiovascular disease in peritoneally dialyzed patients. Thromb Res
http://www.ncbi.nlm.nih.gov/pubmed/19732942

Ray MJ, Juneja M, Bett N, and Walters DL (2009) A comparison of anticoagulation with bivalirudin and provisional GPIIb/IIIa inhibition with unfractionated heparin and mandatory GPIIb/IIIa inhibition during percutaneous coronary intervention in relation to platelet activation and the inhibition of coagulation. EuroIntervention 5:330-335.
http://www.ncbi.nlm.nih.gov/pubmed/19736157

Rousseau A, Robert A, Gerotziafas G, Torchin D, Zannad F, Lacut K, Libersa C, Dasque E, Demolis JL, Elalamy I, and Simon T (2009) Effect of two oral doses of 17beta-estradiol associated with dydrogesterone on thrombin generation in healthy menopausal women: A randomized double-blind placebo-controlled study. Fundam Clin Pharmacol
http://www.ncbi.nlm.nih.gov/pubmed/19719551

Satoh SI, Hitomi A, Ikegaki I, Kawasaki K, Nakazono O, Iwasaki M, Mohri M, and Asano T (2009) Amelioration of endothelial damage/dysfunction is a possible mechanism for the neuroprotective effects of Rho-kinase inhibitors against ischemic brain damage. Brain Res Bull
http://www.ncbi.nlm.nih.gov/pubmed/19723568

Sorensen B, Asvaldsdottir HS, Gudmundsdottir BR, and Onundarson PT (2009) The combination of recombinant factor VIIa and fibrinogen correct clotting ex vivo in patient samples obtained following cardiopulmonary bypass surgery. Thromb Res
http://www.ncbi.nlm.nih.gov/pubmed/19733387

Spivey MH and Duffy MR (2009) Traumatic haemorrhage: A role for recombinant factor VIIa? Anaesthesia 64:1141-1142.
http://www.ncbi.nlm.nih.gov/pubmed/19735409

Tang R, Long J, and Chen B (2009) [Expression of integrin alphavbeta3, tissue factor, and vascular endothelial growth factor in experimental choroidal neovascularization.]. Zhong Nan Da Xue Xue Bao Yi Xue Ban 34:762-767.
http://www.ncbi.nlm.nih.gov/pubmed/19734584

Yun TH and Morrissey JH (2009) Polyphosphate and omptins: Novel bacterial procoagulant agents. J Cell Mol Med
http://www.ncbi.nlm.nih.gov/pubmed/19725923

Zhou H, Wang H, Li N, Yu Y, Huang H, Yan Y, and Wang T (2009) Annexin A2 mediates anti-beta2GPI/beta2GPI-induced tissue factor expression on monocytes. Int J Mol Med 24:557-562.
http://www.ncbi.nlm.nih.gov/pubmed/19724897

Zou YN, Hou JB, Zhang Y, Nie HG, Liu HX, and Yu B (2009) [Ad-TFPI gene transfer attenuates intimal proliferation in rabbit carotid arteries after balloon injury]. Zhonghua Xin Xue Guan Bing Za Zhi 37:169-173.
http://www.ncbi.nlm.nih.gov/pubmed/19719999
______________________________________________________
ABOUT TRIGGER

TRIGGER is edited by Jim Morrissey and Pierre Neuenschwander, with editorial assistance by Genie Morrissey. It includes Abstracts of Papers in Press, Meeting Announcements, Positions Sought/Available,or any other pertinent item that subscribers may want to share with their colleagues. To submit an item for publication in Trigger, e-mail us. To request or cancel a subscription,or for more information about TRIGGER or the biology of tissue factor and factor VII, visit our web site. You can also contact us by mail: J.H. Morrissey, University of Illinois College of Medicine, 417 Med Sci Bldg MC-714, 506 S. Mathews Ave., Urbana, IL 61801, USA.

DISCLAIMER: TRIGGER is provided "as is" for information purposes only and without warranty of any kind, express or implied. Users shall assume the entire risk as to the accuracy and usefulness of information in TRIGGER. Opinions expressed here are not necessarily those of the editors or their employers. You may share TRIGGER with your scientific colleagues but you are not permitted to use it or its contents for commercial purposes.
__________________________________________________________